Edition:
India

Aslan Pharmaceuticals Ltd (ASLN.OQ)

ASLN.OQ on NASDAQ Stock Exchange Global Market

3.20USD
1:30am IST
Change (% chg)

$-0.02 (-0.62%)
Prev Close
$3.22
Open
$3.25
Day's High
$3.25
Day's Low
$3.20
Volume
242
Avg. Vol
3,298
52-wk High
$8.48
52-wk Low
$2.52

Latest Key Developments (Source: Significant Developments)

Aslan Pharmaceuticals Files Preliminary Prospectus Related To Offering ADS
Friday, 31 May 2019 

May 31 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS LTD FILES PRELIMINARY PROSPECTUS RELATED TO OFFERING OF UP TO $15 MILLION AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Aslan Pharmaceuticals Announces Strategic Prioritisation Of Clinical Development Programs And Corporate Restructuring
Wednesday, 30 Jan 2019 

Jan 29 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ANNOUNCES STRATEGIC PRIORITISATION OF CLINICAL DEVELOPMENT PROGRAMS AND CORPORATE RESTRUCTURING.ASLAN PHARMACEUTICALS - WILL FOCUS RESOURCES ON LATE-STAGE DEVELOPMENT OF VARLITINIB AS A POTENTIAL NOVEL TREATMENT FOR FIRST- AND SECOND-LINE BTC.ASLAN PHARMACEUTICALS LTD - FOLLOWING THIS STRATEGIC REVIEW, ASLAN WILL REDUCE ITS COST BASE, INCLUDING A REDUCTION IN HEADCOUNT BY 30%.ASLAN PHARMACEUTICALS LTD - CLINICAL DEVELOPMENT OF ASLAN003 IN AML AND ASLAN004 IN ATOPIC DERMATITIS REMAINS ON TRACK..ASLAN PHARMACEUTICALS LTD - BERTIL LINDMARK, CURRENTLY CHIEF MEDICAL OFFICER, HAS ANNOUNCED HE WILL RETIRE.ASLAN PHARMACEUTICALS LTD - DOES NOT EXPECT TO INCUR ANY MATERIAL RESTRUCTURING CHARGES.ASLAN PHARMACEUTICALS LTD - MARK MCHALE, CHIEF OPERATING OFFICER, WILL TRANSITION TO ROLE OF CHIEF DEVELOPMENT OFFICER.ASLAN PHARMACEUTICALS LTD - PLANNED CHANGES WILL LOWER OPERATIONAL COSTS BY 50%.ASLAN PHARMACEUTICALS - ASLAN WILL BE CLOSING ONGOING SINGLE-ARM SECOND-LINE BTC STUDY IN CHINA AS IT IS NOW EXPECTED TO READ OUT AFTER TREETOPP STUDY.  Full Article

Aslan Pharma Updates Timelines For Clinical Trial Of Varlitinib In Biliary Tract Cancer In China
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS PROVIDES UPDATE ON TIMELINES FOR CLINICAL TRIAL OF VARLITINIB IN BILIARY TRACT CANCER IN CHINA.ASLAN PHARMACEUTICALS - AGREED THAT A PROTOCOL AMENDMENT SHOULD BE SUBMITTED TO TO MODIFY ENROLMENT CRITERIA.ASLAN PHARMACEUTICALS - AGREED THAT PROTOCOL AMENDMENT SHOULD BE SUBMITTED TO ENSURE STUDY WILL PROVIDE ACCURATE EVALUATION OF VARLITINIB'S EFFICACY.ASLAN PHARMACEUTICALS LTD - REVIEW AND IMPLEMENTATION OF VOLUNTARY AMENDMENT IS EXPECTED TO TAKE APPROXIMATELY 4 MONTHS.ASLAN PHARMACEUTICALS LTD - WILL CONTINUE TO RECRUIT PATIENTS INTO STUDY AND PROVIDE A FURTHER UPDATE ON STUDY TIMELINES IN EARLY 2019.ASLAN - PATIENTS ENROLLED IN SECOND LINE APPEAR TO HAVE PERFORMED SIGNIFICANTLY WORSE, PRIOR TO RECRUITMENT, IN FIRST LINE SETTING VERSUS GLOBAL STUDIES.ASLAN PHARMACEUTICALS LTD - DO NOT SEE ANY IMPACT ON OTHER ONGOING PLACEBO-CONTROLLED STUDIES.  Full Article

Aslan Pharmaceuticals unit to issue 67 mln new shares at T$38 per share
Monday, 13 Nov 2017 

Nov 13(Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO> ::Says its unit ASLAN Pharmaceuticals Pte. Ltd plans to issue 67 million new shares at T$38 per share .  Full Article

Aslan Pharmaceuticals plan private placement of up to 45 mln shares
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO> ::Says it plans to issue up to 45 million new shares via private placement, with details remaining to be determined .  Full Article